AI-CVD vs CAC Software
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary goal is comprehensive, opportunistic screening for a wide range of cardiovascular and multisystem diseases using existing CT scans. This platform is ideal for identifying hidden health risks like cardiac chamber abnormalities, epicardial fat, and aortic calcification without requiring additional imaging or disrupting current workflows.
View AI-CVD →Choose CAC Software if…
Choose Imbio's CAC Software if your focus is specifically on detailed and automated quantification of coronary artery calcification for precise coronary artery disease risk assessment. This tool excels at generating Agatston scores, arterial age, and 3D visualizations from non-contrast chest CTs, seamlessly integrating into existing DICOM viewing workflows for focused cardiac analysis.
View CAC Software →For physicians evaluating AI tools for cardiovascular risk assessment, AI-CVD from HeartLung Corporation and Imbio’s CAC Software offer distinct approaches. AI-CVD is a comprehensive platform designed for opportunistic screening, leveraging existing CT scans to detect a broader range of cardiovascular and multisystem diseases. It excels at providing automated measurements for various cardiac structures, including coronary artery calcium (CAC) scoring, aortic and mitral valve calcification, and cardiac chamber volumetry, all without requiring additional imaging or workflow disruption. This makes it ideal for practices seeking a tool that can uncover hidden risks across multiple systems from routine scans.
In contrast, Imbio’s CAC Software is specifically focused on the precise quantification of coronary artery calcification. It provides detailed outputs such as Agatston score, arterial age, and calcified lesion mass and volume, along with 3D visualizations, directly integrating into existing DICOM viewing workflows. The key practical difference lies in their scope: AI-CVD offers a broader, multi-system screening capability, while Imbio’s CAC Software provides a deeper, more specialized analysis of coronary artery calcification. Physicians prioritizing a wide-net opportunistic screening for various cardiovascular and systemic issues from existing CTs might lean towards AI-CVD. Conversely, those primarily focused on highly detailed and specific coronary artery calcification analysis for risk assessment, seamlessly integrated into their current imaging workflow, would find Imbio’s CAC Software more suitable.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-CVD | CAC Software |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Cloud | Cloud, On-premise, Partner platforms |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AI-CVDAI-CVD emphasizes 'no additional imaging, radiation, contrast, or workflow disruption' and can transform any chest CT (cardiac-gated or low-dose lung CT) into a multidimensional assessment, suggesting broad applicability with minimal user effort. While CAC Software also integrates into existing DICOM workflows and provides automated analysis, AI-CVD's ability to leverage a wider variety of existing CT scans for comprehensive screening gives it a slight edge in seamless integration and reduced burden.
Clinical Value
AI-CVDAI-CVD offers a significantly broader range of clinical insights, performing opportunistic screening for cardiovascular and multisystem diseases, including various calcium analyses, cardiac chamber volumetry, epicardial fat, aorta/pulmonary artery sizing, lung attenuation, liver attenuation, bone mineral density, and muscle-fat composition. This comprehensive approach, cleared by the FDA for ten opportunistic screening indications, extends well beyond CAC quantification to predict conditions like heart failure, atrial fibrillation, and stroke, providing substantially higher clinical value.
Pricing & Value
AI-CVDBoth tools require contacting the vendor for pricing, resulting in a tie for pricing transparency. However, AI-CVD's extensive capabilities for multisystem opportunistic screening and its potential to generate new downstream revenue for health systems through preventive cardiology and interventions suggest a higher overall value proposition.
Enterprise Readiness
CAC SoftwareCAC Software explicitly states third-party HIPAA and GDPR compliance certification and offers flexible deployment options including Cloud, On-premise, and Partner platforms. In contrast, AI-CVD's JSON indicates 'Likely, contact vendor' for BAA and HIPAA, which, while clarified by their privacy policy, is less definitive than Imbio's explicit certifications and broader deployment flexibility.
Innovation
AI-CVDAI-CVD demonstrates greater innovation by integrating multiple FDA-cleared AI modules into a unified platform for comprehensive, multisystem opportunistic screening from existing CT scans. This platform goes beyond traditional CAC scoring to predict a wider array of conditions and even refines the 'Agatston zero' concept, representing a significant advancement in preventive medicine.
Support & Docs
CAC SoftwareImbio's CAC Software clearly outlines its support channels, including phone and email, with specified support hours, and explicitly states the availability of user manuals and FAQs upon request. AI-CVD's information on support and documentation is not as readily available or detailed in the provided data or search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | CAC Software |
|---|---|---|
| Name | AI-CVD | CAC Software |
| Company | HeartLung Corporation | Imbio |
| Description | AI-CVDu00ae is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | Imbio's Coronary Artery Calcification (CAC) software is a set of automated image post-processing algorithms designed to help radiologists and cardiologists determine the location and calculate the amount of calcification within the coronary arteries in patients who have undergone a non-contrast, chest computed tomography (CT). |
| Key Features (Coronary Artery Calcification) | Coronary Artery Calcium (CAC) scoring | Automated image post-processing for coronary artery calcification, Quantification of calcification within coronary arteries, Outputs Agatston score, arterial age, calcified lesion mass and volume, Provides 3D visualizations and annotated images, Non-invasive analysis from non-contrast chest CT scans, Integrates into existing DICOM viewing workflow, Supports risk assessment for coronary artery disease, Deep-learning based analysis |
| Additional Key Features (Beyond CAC) | Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing, Lung attenuation analysis, Liver attenuation analysis, Bone mineral density and muscleu2013fat composition | Not specified |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and CAC Software.